{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:10:57Z","timestamp":1771272657352,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.pharma.2016.12.006","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T06:15:44Z","timestamp":1486620944000},"page":"172-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case report of rare palmoplantar keratosis and nail dystrophy with imatinib"],"prefix":"10.1016","volume":"75","author":[{"given":"M.","family":"Benabbes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Tazi Mezalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Meddah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharma.2016.12.006_bib0080","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.pharma.2016.12.006_bib0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.pharma.2016.12.006_bib0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2340\/00015555-0758","article-title":"Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature","volume":"90","author":"Kuraishi","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.pharma.2016.12.006_bib0095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4103\/0019-5154.117315","article-title":"Generalized lichenoid drug eruption associated with imatinib mesylate therapy","volume":"58","author":"Ghosh","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"8","key":"10.1016\/j.pharma.2016.12.006_bib0100","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2016.12.006_bib0105","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0151-9638(07)89201-5","article-title":"Prise en charge globale des toxidermies","volume":"134","author":"Barbaud","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.pharma.2016.12.006_bib0110","series-title":"Common terminology criteria for adverse events V4.0 (CTCAE)","year":"2009"},{"issue":"2","key":"10.1016\/j.pharma.2016.12.006_bib0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.monrhu.2010.02.007","article-title":"Crit\u00e8res d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments","volume":"77","author":"Bannwarth","year":"2010","journal-title":"Revue du Rhumatisme Monographies"},{"issue":"6","key":"10.1016\/j.pharma.2016.12.006_bib0120","first-page":"517","article-title":"R\u00e9actualisation de la m\u00e9thode fran\u00e7aise d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments","volume":"66","author":"Arimone","year":"2011","journal-title":"Th\u00e9rapie"},{"issue":"10","key":"10.1016\/j.pharma.2016.12.006_bib0125","first-page":"535","article-title":"Survol des k\u00e9ratodermies palmo plantaires acquises","volume":"65","author":"Devillers","year":"2010","journal-title":"Rev Med Li\u00e8ge"},{"issue":"2","key":"10.1016\/j.pharma.2016.12.006_bib0130","first-page":"1","article-title":"K\u00e9ratodermies palmoplantaires","volume":"8","author":"Stambouli","year":"2012","journal-title":"EMC - Podologie"},{"issue":"5\u20136","key":"10.1016\/j.pharma.2016.12.006_bib0135","first-page":"339","article-title":"R\u00e9actions cutan\u00e9es ind\u00e9sirables des traitements par anticorps monoclonaux","volume":"64","author":"Pi\u00e9rard-Franchimont","year":"2009","journal-title":"Rev Med Liege"},{"issue":"4","key":"10.1016\/j.pharma.2016.12.006_bib0140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.5021\/ad.2013.25.4.526","article-title":"Plantar keratoderma with pachyonychia likely induced by imatinib mesylate","volume":"25","author":"Kim","year":"2013","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.pharma.2016.12.006_bib0145","series-title":"Individual Case Safety Report. The Uppsala Monitoring Centre","year":"2015"},{"issue":"6","key":"10.1016\/j.pharma.2016.12.006_bib0150","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1365-2133.2006.07262.x","article-title":"Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia","volume":"154","author":"Deguchi","year":"2006","journal-title":"Br J Dermatol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450916301298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450916301298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:32:14Z","timestamp":1757719934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450916301298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0003450916301298"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2016.12.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case report of rare palmoplantar keratosis and nail dystrophy with imatinib","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2016.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}